| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1986Sci...232..727W |
| P356 | DOI | 10.1126/SCIENCE.3008337 |
| P698 | PubMed publication ID | 3008337 |
| P2093 | author name string | Waldmann TA | |
| P433 | issue | 4751 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 727-732 | |
| P577 | publication date | 1986-05-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes | |
| P478 | volume | 232 |
| Q41644696 | A chimeric mouse/human anti-IL-2 receptor antibody with enhanced biological activities |
| Q33849871 | A(2A) adenosine receptors in human peripheral blood cells |
| Q36793381 | Abnormal intracellular sorting of O-linked carbohydrate-deficient interleukin-2 receptors |
| Q67759038 | Activation of Mononuclear Immune Cells in Response to Staphylococcal Lipoteichoic Acid |
| Q39559552 | Advances in human retroviruses |
| Q34071328 | Advances in interleukin 2 receptor targeted treatment |
| Q74554195 | Advances in the management of cutaneous T-cell lymphoma |
| Q39754076 | Alpha interferons in B-cell neoplasms |
| Q43767780 | Altered T-cell subsets and defective T-cell function in young children with Down syndrome (trisomy-21). |
| Q41136639 | An immunohistochemical characterisation of the inflammatory cell infiltrate in benign and malignant prostatic disease |
| Q70039421 | An immunohistologic study of the distribution and status of activation of head and neck tumor infiltrating leukocytes |
| Q52542784 | Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. |
| Q36704838 | Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey |
| Q37457154 | Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival |
| Q37605247 | Antibody-based therapy of leukaemia |
| Q47803013 | Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides |
| Q44223669 | Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene |
| Q33647489 | Automatic microinjection system facilitates detection of growth inhibitory mRNA |
| Q68134945 | Autotransplanted jejunum in patients with carcinomas of the head and neck: transport of immunosurveillance against tumor cells? |
| Q70037740 | BCG induced CD4+ cytotoxic T cells from BCG vaccinated healthy subjects: relation between cytotoxicity and suppression in vitro |
| Q67551296 | Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients |
| Q42106899 | Biological significance of soluble IL-2 receptor |
| Q33645011 | Blockade of the interleukin-2 receptor by anti-Tac antibody inhibits the generation of antigen-nonspecific suppressor T cells in vitro |
| Q38199347 | CD28z CARs and armored CARs |
| Q45673107 | Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells |
| Q36889122 | Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection |
| Q36931461 | Characterization of circulating CD4+ CD8+ lymphocytes in healthy individuals prompted by identification of a blood donor with a markedly elevated level of CD4+ CD8+ lymphocytes |
| Q35103298 | Characterization of rat T helper cell clones specific for Bacteroides gingivalis antigen |
| Q24293092 | Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies |
| Q37878307 | Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms |
| Q35757313 | Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. |
| Q33892988 | Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma |
| Q53090167 | Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. |
| Q37427559 | Comparison of constitutive and inducible transcriptional enhancement mediated by kappa B-related sequences: modulation of activity in B cells by human T-cell leukemia virus type I tax gene |
| Q34632128 | Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex |
| Q35746649 | Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen |
| Q47443294 | Cytokines in Cancer Immunotherapy |
| Q37162174 | Cytokines in clinical and experimental transplantation |
| Q89062087 | Cytokines in the Treatment of Cancer |
| Q36832132 | Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma |
| Q34379078 | Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients |
| Q44257539 | Deficient interleukin-2 responsiveness of T lymphocytes from patients with primary biliary cirrhosis |
| Q37412425 | Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex |
| Q36946771 | Denileukin diftitox as novel targeted therapy for lymphoid malignancies |
| Q37316082 | Depleting T-cell subpopulations in organ transplantation |
| Q46080463 | Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1? and soluble interleukin-2 receptor production |
| Q35817589 | Detection of activated T lymphocytes in the human atherosclerotic plaque |
| Q41157625 | Determination of cell-free interleukin 2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity |
| Q39713772 | Development and characterization of mouse monoclonal antibodies reactive with chicken interleukin-2 receptor αlpha chain (CD25). |
| Q34189072 | Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription |
| Q70330920 | Diagnostic and prognostic value of immunohistological bone marrow examination: results in 212 patients with lymphoproliferative disorders |
| Q41108970 | Differential activity of progesterone and glucocorticoid receptors on mouse mammary tumor virus templates differing in chromatin structure |
| Q34265069 | Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor |
| Q72649390 | Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease |
| Q35855947 | Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases |
| Q35818645 | Early induction of MHC antigens in human liver grafts. An immunohistologic study |
| Q41117813 | Effect of lipid emulsion on IL-2 production by mononuclear cells of newborn infants and adults |
| Q72795685 | Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers |
| Q34244205 | Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes |
| Q79886528 | Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib |
| Q45734166 | Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway |
| Q38879567 | Evaluation of CD25-positive cells in relation to the subtypes and prognoses in various lymphoid tumours in dogs |
| Q42048730 | Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining |
| Q42939845 | Expansion of natural killer cells but not T cells in human interleukin 2/interleukin 2 receptor (Tac) transgenic mice |
| Q36351122 | Expression and role of p75 interleukin 2 receptor on human monocytes |
| Q35816721 | Expression of growth factor/receptor genes in postthymic T cell malignancies |
| Q77659259 | Failure of treatment with interleukin-2 receptor-specific monoclonal antibody in acute coxsackievirus B3 myocarditis in mice |
| Q34354712 | Flow cytometric resonance energy transfer measurements support the association of a 95-kDa peptide termed T27 with the 55-kDa Tac peptide |
| Q69194759 | Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells |
| Q33890975 | Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions. |
| Q40826903 | Functional characterization of a swine CD4(+)/CD8(+) double positive lymphoblastoid T-cell line with a CD25(+)/CD45RA(-) phenotype generated in vitro with interleukin-2. |
| Q34663527 | GFP affects human T cell activation and cytokine production following in vitro stimulation |
| Q33557888 | Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens |
| Q40922549 | Granulocyte-macrophage colony-stimulating factor. Sensitive and receptor-mediated regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral blood lymphocytes |
| Q28731819 | Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy |
| Q42116563 | HIV-associated myocarditis. Pathology and immunopathology. |
| Q52508966 | High expression of adhesion molecules/activation markers with little interleukin-2, interferon γ, and tumor necrosis factor β gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma |
| Q36353203 | Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens |
| Q35811193 | IL-2 mRNA expression in Tac-positive malignant lymphomas |
| Q42738292 | IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. |
| Q72920767 | IL-2 receptor gene expression and IL-2 production by human preterm newborns' cells |
| Q39593725 | Identification of two intracellular mechanisms leading to reduced expression of oncoretrovirus envelope glycoproteins at the cell surface |
| Q67667623 | Immune activation and T cell subset abnormalities in circulation of patients with recently diagnosed type I diabetes mellitus |
| Q36634875 | Immune activation and viral burden in acute disease induced by simian immunodeficiency virus SIVsmmPBj14: correlation between in vitro and in vivo events. |
| Q35830318 | Immunohistochemical localization of granzyme B antigen in cytotoxic cells in human tissues |
| Q41114975 | Immunologic dysfunction in cancer |
| Q35948405 | Immunological studies in patients with HBsAg-positive chronic active hepatitis--spontaneous lymphocyte transformation and natural killer cell activity |
| Q37019610 | Immunoregulatory role of the spleen in antibody responses to pneumococcal polysaccharide antigens |
| Q36181177 | Immunoscreening protocols for the identification of clinically useful antibodies and antigens |
| Q40931187 | Immunotoxins for treatment of leukemia and lymphoma |
| Q35224573 | Impaired expression of interleukin 2 receptor and CD45RO antigen on lymphocytes from children with acute lymphoblastic leukemia in response to cytomegalovirus and varicella-zoster virus |
| Q45060450 | Improvement in the antibody productivity of human-human hybridomas by transfection with Tac gene |
| Q48362877 | In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis. |
| Q68664280 | Inability of mitogen-stimulated spleen cells from newborn mice to synthesize interleukin-2 receptors |
| Q36362874 | Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis |
| Q24336470 | Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors |
| Q52128043 | Inhibitory activity of cyclosporine is dependent on the activating signal(s) provided to T cells. |
| Q70327682 | Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes |
| Q34191473 | Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells |
| Q36354517 | Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein |
| Q41034927 | Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes |
| Q45366937 | Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro |
| Q41483401 | Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies |
| Q54112435 | Interleukin-2 induced mitogenesis of human peripheral blood T-lymphocytes: role of accessory cells. |
| Q42129949 | Interleukin-2 production of lymphocytes in food sensitive atopic dermatitis |
| Q44493607 | Intravenous daclizumab for recalcitrant ocular inflammatory disease |
| Q41390488 | Involvement of the interleukin-2 receptor gamma subunit in interleukin-4-dependent activation of mouse hematopoietic cells and splenic B cells |
| Q45735488 | Lack of induction of interleukin-2-receptor-alpha in patients with tuberculosis and human immunodeficiency virus co-infection: implications for pathogenesis |
| Q36873427 | Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease |
| Q72860300 | Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes |
| Q39571001 | Luminescence spectroscopic approaches in studying cell surface dynamics |
| Q73389154 | Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2) |
| Q70395259 | Mechanisms underlying T-lymphocyte activation: mitogen initiates and IL-2 amplifies the expression of transferrin receptors via intracellular iron level |
| Q68103529 | Medium-scale ligand-affinity purification of two soluble forms of human interleukin-2 receptor |
| Q36218708 | Mitogen activation induces the enhanced synthesis of two heat-shock proteins in human lymphocytes |
| Q37755851 | Monoclonal antibodies in diagnosis and therapy |
| Q35451349 | Monoclonal antibodies in renal transplantation: a review |
| Q69041463 | Multiple sclerosis: effect of myelin basic protein on interleukin 1, interleukin 2 production and interleukin 2 receptor expression in vitro |
| Q33893147 | Murine interleukin 2 receptor beta chain: dysregulated gene expression in lymphoma line EL-4 caused by a promoter insertion |
| Q70175794 | NDA3: a differentiation antigen associated with the receptor for B cell growth factor |
| Q53533346 | Oncogenetics. A new emerging field of cancer. |
| Q35831183 | Peripheral T-cell lymphomas. Immunophenotype, lymphokine production, and immunologic functional characteristics of the lymph-node malignant T cells. |
| Q47866311 | Peripheral blood mononuclear cells in the squirrel monkey Saimiri sciureus II. — Exploration of the IL2/IL2R pathway of T-cell activation |
| Q35021504 | Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes |
| Q52831745 | Phenotypic characteristics of three human non-Hodgkin lymphoma lines: flow cytometric analysis after long-term maintenance. |
| Q43085328 | Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. |
| Q37196716 | Receptor-directed therapy of T-cell leukemias and lymphomas |
| Q34287109 | Recombinant interleukin 2 therapy in severe combined immunodeficiency disease |
| Q35092957 | Reduced suppressor cell response to Mycobacterium leprae in lepromatous leprosy |
| Q67737201 | Regulation of IL-2 beta receptor expression and beta-chain mRNA by human thymocytes |
| Q47580710 | Relationship between eosinophil density and T-cell activation markers in lymph nodes of patients with Hodgkin's disease |
| Q41017130 | Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells |
| Q36961056 | Role and regulation of interleukin (IL)-2 receptor alpha and beta chains in IL-2-driven B-cell growth |
| Q41148049 | Role of interleukin-2 in human hematological malignancies |
| Q41331795 | Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. |
| Q69741866 | Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation |
| Q70341004 | Simultaneous increased expression of E-rosette receptor (CD2, T11) and T cell growth factor receptor on human T lymphocytes during activation |
| Q40838126 | Strategies for treatment of myasthenia gravis |
| Q27664283 | Structural basis of immunosuppression by the therapeutic antibody daclizumab |
| Q45840009 | Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. |
| Q42851815 | Suppression of ovine lymphocyte activation by Teladorsagia circumcincta larval excretory-secretory products. |
| Q39524176 | Surface proteins and glycoproteins of human leucocytes |
| Q33220872 | Systemic immunostimulation after retinal laser treatment in retinitis pigmentosa |
| Q74046172 | Systemic inflammatory responses in acute coronary syndrome: increased activity observed in polymorphonuclear leukocytes but not T lymphocytes |
| Q67990966 | T-cell abnormality and defective interleukin-2 production in patients with carcinoma of the urinary bladder with schistosomiasis |
| Q36881884 | T-cell activation by autologous human T-cell leukemia virus type I-infected T-cell clones |
| Q67753687 | T-cell chronic lymphocytic leukemia: T-cell function and lymphokine secretion |
| Q99591448 | Targeting Receptors on Cancer Cells with Protein Toxins |
| Q34630134 | The IL-2/IL-15 receptor systems: targets for immunotherapy |
| Q91785148 | The RNA binding protein Sam68 controls T helper 1 differentiation and anti-mycobacterial response through modulation of miR-29 |
| Q39595329 | The arrangement of immunoglobulin and T cell receptor genes in human lymphoproliferative disorders. |
| Q67905076 | The control of class II expression on T cells is independent of the regulation of Tac and the induction of proliferation |
| Q94329676 | The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators |
| Q33832658 | The interleukin 2 gene is expressed in the syncytiotrophoblast of the human placenta |
| Q39560514 | The interleukins in acquired disease |
| Q34334821 | The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells |
| Q39044411 | The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells |
| Q38665434 | The regulators of complement activation (RCA) gene cluster |
| Q43651719 | The relationship between epithelial Ia expression and the inflammatory cell infiltrate during experimental oral carcinogenesis |
| Q34659968 | The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation |
| Q73539251 | The use of interleukin-2 receptor expression as a marker of cell-mediated immunity in goats experimentally infected with Mycobacterium avium ssp. paratuberculosis |
| Q68298980 | Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia |
| Q69056953 | Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations |
| Q44512137 | Treatment of graft-versus-host disease after liver transplantation with basiliximab followed by bowel resection. |
| Q74264520 | [New induction immunosuppression treatments in kidney transplantation] |
| Q36875711 | c-fos gene induction by interleukin 2: identification of the critical cytoplasmic regions within the interleukin 2 receptor beta chain |
Search more.